SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-22-000040
Filing Date
2022-08-08
Accepted
2022-08-08 16:08:56
Documents
14
Period of Report
2022-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctic-20220808.htm   iXBRL 8-K 36925
2 EX-99.1 ex991earningsreleaseq22022.htm EX-99.1 88920
6 cti_logoxrgbx1501.jpg GRAPHIC 25747
  Complete submission text file 0000891293-22-000040.txt   307545

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20220808.xsd EX-101.SCH 1927
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20220808_lab.xml EX-101.LAB 24197
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20220808_pre.xml EX-101.PRE 12543
8 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20220808_htm.xml XML 10565
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 221144417
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences